Alzheimer’s Memory Center is experienced in the following types of clinical trials:
- Pharmacokinetic/Pharmacodynamic
- Dose Ranging Studies
- Drug-Drug Interaction Studies
- Safety & Efficacy
- Proof of Concept Studies
- Outpatient Studies
AMC has a database of more than 5,000 individuals that includes private patients, individuals who have participated in clinical trials, and those who have expressed an interest in participating in clinical trials. In addition to our database, Dr. Bolouri is well respected in the local community and has access to a network of physicians to exchange ideas and enhance best practices in patient recruitment. We are conveniently located in the heart of Charlotte, NC, minutes away from several major hospitals with easy access to multiple freeways and an international airport.
Our comprehensive research facility includes:
- Multiple examination and consultation rooms
- Psychometrics evaluation rooms
- An on-site CLIA-certified lab
- A monitoring area
- Secured investigational drug and specimen storage facilities
- -20 & -70 degree Freezers for lab specimen storage
- An infusion suite
- ECG machine
Dr. Bolouri has partnered with the following pharmaceutical sponsors:
- Abbott Laboratories
- AstraZeneca
- Astra-Merck
- Athena Neurosciences
- Baker-Norton Pharmaceuticals
- Battelle
- Bayer
- Biovail
- Boehringer Ingelheim
- Bristol Myers Squibb
- CIBA-Geigy Pharmaceuticals
- Eisai
- Eli Lilly and Company
- Forest Laboratories
- Glaxo INC.
- Hoechst-Roussel
- Hoffman-La Roche
- Janssen Research Foundation
- Lundbeck
- Marion Merrill Dow
- Merck Research Laboratories
- Merck, Sharp and Dohme
- Merz
- Miles INC.
- Novartis
- Organon Akzo Nobel
- Parke-Davis
- Pfizer
- Protodigm
- Sandoz
- Sanofi
- Schwabe
- Sigma-Tau Pharmaceuticals
- Smithkline-Beecham
- Somerset
- Takeda
- Toyama
- University of California
- Upjohn Laboratories
- Warner Lambert Parke Davis
- Wyeth Ayerst
Research Experience:
- The efficacy and safety of Depakote in subjects with migraines
- An open label study for the safety of long term Tiagabine HCl in subjects with epilepsy
- A randomized, double blind, placebo controlled, comparison of the study drug to placebo in subjects with painful diabetic polyneuropathy
- A randomized, placebo-controlled, double-blind, 16 week study of the safety and tolerability of the study medication in patients with mild to moderate Alzheimer’s disease
- A placebo-controlled, dose ranging safety and tolerability pilot study of remacemide hydrochloride in subjects with probable Alzheimer’s disease
- A double blind randomized, placebo controlled study to access the efficacy and tolerability of Tizanidine tablets for inpatients suffering from spasticity due to Multiple Sclerosis
- An open label long tern study to evaluate the safety of Tizanidine tablets in patients suffering from spasticity due to Multiple Sclerosis
- A double-blind, placebo controlled study of Alzene in Alzheimer’s patients with mild to moderately severe cognitive decline
- Delay in nursing home placement of Alzheimer’s disease patients treated with the Aricept Clinical Program
- Multicenter, open label study of the safety and tolerability of Metrifonate in patients with probable Alzheimer’s disease
- Double-blind, placebo-controlled trial to evaluate the safety and efficacy of fixed-dose Metrifonate tablets in patients with probable Alzheimer’s disease
- Trial to evaluate the safety and efficacy of a fixed-dose Metrifonate tablet comparing a loading dose phase and no loading dose phase vs placebo in patients with probable Alzheimer’s disease
- Open-label study of the safety and tolerability of Metrifonate in patients with probable Alzheimer’s disease.
- Long-term treatment with Metrifonate for patients with probable Alzheimer’s disease.
- A double-blind, active controlled trial to evaluate the safety of switching patients with mild to moderate Alzheimer’s disease from Donepezil to Metrifonate
- Study of the efficacy, safety and tolerability 30mg and 90mg Buspirone hydrochloride extended release compared to placebo in patients with generalized Anxiety Disorder
- Efficacy, safety and tolerability of up to 90mg Buspirone hydrochloride Extended Release in patients with Generalized Anxiety Disorder
- Efficacy and safety of 6, 12, 24 and 36 mg tid po and 36mg bid po Talsaclidine (free base) for 12 weeks in patients with mild to moderate dementia of Alzheimer’s type
- Long-term safety and tolerability of oral administration of Talsaclidine 24mg TID in patients with mild to moderate dementia of the Alzheimer type
- An open multi-center trial of Nefazodone on the treatment of patients with mood disorders
- Trial of Nefazodone vs placebo in the treatment of elderly depressed outpatients
- Oxiracetam in the treatment of primary degenerative dementia of mild to moderate severity, low dose schedule
- Oxiracetam in the treatment of primary degenerative dementia of mild to moderate severity, high dose schedule
- Oxiracetam in the treatment of multiple infarct dementia mild to moderate severity, low dose schedule
- Preliminary study to determine the efficacy and safety of donepezil hydrochloride in patients with persistent mild to moderate memory impairments resulting from a single closed head injury
- Evaluation of the study and efficacy of the study drug in patients with Alzheimer’s disease
- A 24 week placebo controlled evaluation of the efficacy and safety of Donepezil Hydrochloride in patients with dementia associated with cerebrovascular disease
- A 30 week, open-label evaluation of Donepezil Hydrochloride in patients in dementia associated with cerebrovascular disease
- 54-week evaluation of the effects of donepezil hydrochloride on function outcomes in patients with Alzheimer’s disease with a stage crossover to open-label donepezil hydrochloride treatment
- open-label trial evaluating the safety and efficacy of donepezil hydrochloride in patients of Alzheimer’s disease
- A 24-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of donepezil hydrochloride in patients with severe Alzheimer’s disease followed by a 12 week open label extension period
- A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of donepezil hydrochloride in patients with early Alzheimer’s disease
- Safety and efficacy of Olanzapine of cognitive symptoms in subjects with mild to moderate Alzheimer’s disease
- Safety and efficacy of the Xanomeline Transdermal Therapeutic System in patients with mild to moderate Alzheimer’s disease
- Open label extension of Xanomeline registration phase efficacy trials using Xanomeline Transdermal Therapeutic System
- Fluoxetine versus sertraline and paroxetine in major depression: comparison of discontinuation-emergent signs and symptoms
- Olanzapine versus risperidone and placebo in the treatment of Psychosis and Associated Behavioral Disturbances in patients with dementia
- R-fluoxetine versus placebo in the treatment of major depression
- The study of Olanzapine and fluoxetine in combination for treatment resistant depression without psychotic features
- The efficacy and safety of long term administration of controlled-release oral Physostigmine in Alzheimer’s disease and senile dementia of the Alzheimer’s type
- A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of Memantine in patients with moderate to severe dementia of the Alzheimer’s type
- A randomized, titration with long-term open-label evaluation of the safety and efficacy of Memantine in patients with moderate to severe dementia of the Alzheimer’s type
- A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of Memantine in patients with mild to moderate dementia of the Alzheimer’s type
- Evaluation of a combined regimen of subcutaneous and oral study medication in the prevention of Migraine recurrence
- A controlled study of Ondansetron in the treatment of Alzheimer’s type dementia
- A controlled study of Ondansetron in the treatment of primary degenerative dementia of the Alzheimer’s type
- A double-blind evaluation of the safety and efficacy of oral Ondansetron in the treatment of patients with panic disorder
- A multi-center, 30 week, double-blind, parallel group safety, tolerance and efficacy comparison of placebo and Mentane in outpatients with Alzheimer’s disease
- A double-blind placebo controlled, parallel group, dose range finding study of Lazabemide in patients with Alzheimer’s disease
- An open label treatment extension study of Lazabemide in patients with Alzheimer’s disease completing protocol
- Evaluation of the safety and efficacy of fixed doses of Sabeluzole vs. placebo in the treatment of patients diagnosed with dementia of the Alzheimer’s type
- Clinical evaluation of efficacy and safety of Sabeluzole in the treatment of Alzheimer’s disease
- Efficacy, tolerability and safety of Galantamine in the treatment of Alzheimer’s disease
- Long-term safety and efficacy of Galantamine in the treatment of Alzheimer’s disease
- Galantamine in the treatment of Alzheimer’s disease: flexible dose range trial
- Safety and efficacy of Galantamine during withdrawal in the treatment of Alzheimer’s disease
- Open-label use of synthetic Galantamine in the treatment of Alzheimer’s disease
- A randomized, placebo-controlled trial to evaluate the efficacy and safety of Galantamine in patients with minimal cognitive impairment clinically at risk for development of probable Alzheimer’s disease
